Sürdürülebilir Kalkınma Amaçları

• 1

Yazarlar

• Akkiprik, Mustafa(1)
• Aksakal, Alperen(1)
• Amuran, Gökçe Gullu(1)
• Aydın, Pelin(1)
• Erzik, Can(1)
• Gulluolu, Bahadir M.(1)
• Halıcı, Zekai(1)
• Karabulut Uzunçakmak, Sevgi(1)
• Karabulut, Sevgi(1)
• Kaya, Handan(1)
• Kaya, Zehra(1)
• Kerget, Ferhan(1)
• Ozer, Ayşe(1)
• Peker, Irem(1)
• Özmen, Tolga(1)

• MakaleAçık Erişim2023Scopus SJRQ2/r/bayburt/12847
  Evaluation of IGFBP5 expression and plasma osteopontin level in COVID-19 patients

  Karabulut Uzunçakmak, Sevgi; Aksakal, Alperen; Kerget, Ferhan; Aydın, Pelin; Halıcı, Zekai

  Purpose: The aim of this study is to investigate insulin-like growth factor binding protein 5 (IGFBP5) expression in coronavirus disease 2019 (COVID-19) patients and its relationships with COVID-19 laboratory findings and plasma osteopontin (OPN) levels. Materials and methods: We enrolled 60 patients with COVID-19 and 30 healthy individuals in this study. mRNA expression of IGFBP5 was measured by RT-PCR. Plasma OPN levels were measured via the ELISA method. Results: Plasma OPN levels were higher and IGFBP5 expression levels were lower in COVID-19 patients than in the healthy individuals (p ​= ​0.0057 and p ​= ​0.0142, respectively). Critically ill patients had higher OPN and lower IGFBP5 than non-critically ill patients. Patients with affected lungs demonstrated increased OPN and decreased IGFBP5 (p ​= ​0.00032 and p ​= ​0.044, respectively). Receiver operating characteristic (ROC) analysis indicated that IGFBP5 expression and OPN levels can be used discriminate non-critically from critically ill patients (p ​= ​0.049; p ​= ​0.0016, respectively). Conclusion: This study demonstrated that patients with a poor prognosis had increased OPN and decreased IGFBP5. High values of OPN and low values of IGFBP5 may be considered as signs of disease severity. Tissue-specific IGFBP5 expression may contribute to understanding the role of IGFBP5 in the lungs in COVID-19 cases.

  • 
  AtıfScopus6·WoS6·OpenAlex6

  İncele
• MakaleAçık Erişim2016Scopus SJRQ3/r/bayburt/13893
  Correlation between the DNA methylation and gene expression of IGFBP5 in breast cancer

  Karabulut, Sevgi; Kaya, Zehra; Amuran, Gökçe Gullu; Peker, Irem; Özmen, Tolga; Gulluolu, Bahadir M.; Kaya, Handan; Erzik, Can; Ozer, Ayşe; Akkiprik, Mustafa

  BACKGROUND: The insulin-like growth factor binding protein5 (IGFBP5) is often dysregulated in human cancers and considered neither a tumor suppressor nor an oncogene. OBJECTIVE: We aim to examine the reason of the changeable gene regulation of IGFBP5 in the case of methylation in breast cancer. METHODS: We used methyl-specific polymerase (MSP) chain reaction to detect CpG methylation of IGFBP5 promoter and exon-I in breast cancer and adjacent tissues. Gene expression is evaluated by quantative polymerase chain reaction (qPCR). RESULTS: IGFBP5 methylation was detected in 24 of 58 (41%) and 54 of 56 (96.5%) promoter and exon-I site respectively in tumor tissues. In adjacent tissues 17 of 58 (29%) and 53 of 56 (96.5%) was methylated. IGFBP5 expression was higher estrogene receptor (ER)(+) than ER(-) patients (p = 0:0549). Beside, we found a positive correlation between the expression of IGFBP5 and G2 tumor grade (p = 0:0131). However, no correlation was observed between IGFBP5 expression and age, menopause or the presence of lymph node metastasis (p > 0:05). CONCLUSIONS: In summary, our results showed that IGFBP5 promoter and exon-I methylation did not have any differences between tumor and adjacent tissues so that IGFBP5 methylation did not change IGFBP5 gene regulation in breast cancer. This is the first study investigating the IGFBP5 gene methylation in breast cancer.

  AtıfScopus9

  İncele